Covid vaccine monitoring: when will a coronavirus vaccine be ready? | World news



vaccines not yet in human trials


Phase 1

vaccines in small-scale safety trials


Phase 2

vaccines in expanded safety trials


Phase 3

vaccines in large-scale efficacy trials



vaccines approved for general use


Source: WHO. Last update 25 August

Researchers around the world are rushing to develop a vaccine for Covid-19, with more than 170 candidate vaccines now being tracked by the World Health Organization (WHO).

Vaccines normally take years of testing and additional time to be produced on a large scale, but scientists hope to develop a vaccine for the coronavirus within 12 to 18 months.

Vaccines mimic the virus – or part of the virus – that they protect against, stimulating the immune system to develop antibodies. They must meet higher safety standards than other drugs because they are given to millions of healthy people.

Recent vaccine news

AstraZeneca has started trials for a drug that could work as a preventative option for healthy people or slow the progression of the disease in those who are already infected.

Russian health officials have approved a vaccine against the coronavirus that has yet to complete clinical trials.

How are vaccines tested?

in the preclinical stage In tests, researchers give the vaccine to animals to see if it triggers an immune response.

In phase 1 In clinical trials, the vaccine is given to a small group of people to determine if it is safe and to learn more about the immune response it elicits.

In phase 2, the vaccine is given to hundreds of people so that scientists can learn more about its safety and correct dosage.

In phase 3, the vaccine is given to thousands of people to confirm its safety – including its rare side effects – and its effectiveness. These trials involve a control group that receives a placebo.

Vaccines in clinical trials

Current phase

Phase completed

University of Oxford / AstraZeneca

The University of Oxford vaccine is administered via a chimpanzee virus, called a vaccine vector. The vector contains the genetic code for the protein peaks found on the coronavirus and triggers a strong immune response in the human body. The vaccine is in a combined Phase 2/3 trial in the UK and recently underwent phase 3 trials in South Africa and Brazil.

BioNTech / Fosun Pharma / Pfizer

Wuhan Institute of Biologics / Sinopharm

The American biotech company Moderna is developing a candidate vaccine that uses messenger RNA (or mRNA) to induce the body to produce viral proteins on its own. No mRNA vaccine has ever been approved for an infectious disease, and Moderna has never brought a product to market. But vaccine supporters say it might be easier to mass produce than traditional vaccines.

The Chinese company Sinovac is developing a vaccine based on inactivated Covid-19 particles. The vaccine has shown a promising safety profile in the early stages of testing and is now entering phase 3 trials in Brazil.

Beijing Institute of Biologics / Sinopharm

CanSino Biologics Inc./ Beijing Biotechnology Institute

Kentucky Bioprocessing, Inc

Cadila Healthcare Limited

Osaka University / AnGes / Takara Bio

Inovio Pharmaceuticals / Institut international des vaccins

Janssen pharmaceutical companies

Anhui Zhifei Longcom Biopharmaceutical / Institute of Microbiology, Chinese Academy of Sciences

Institute of Medical Biology, Chinese Academy of Medical Sciences

University of Queensland / CSL / Seqirus

People’s Liberation Army (APL) / Walvax Biotech Academy of Military Sciences.

Institut Pasteur / Themis / Univ. de Pittsburgh CVR / Merck Sharp & Dohme

Finlay Vaccine Institute, Cuba

Medigen Vaccine Biologics Corporation / NIAID / Dynavax

Clover Biopharmaceuticals Inc./GSK/Dynavax

ReiThera / LEUKOCARE / Univercells

Gamaleya Research Institute

University of Melbourne / Murdoch Children’s Research Institute

The Murdoch Children’s Research Institute in Australia is conducting a phase 3 trial using an almost 100-year-old tuberculosis vaccine. The vaccine is not believed to protect directly against Covid-19, but could stimulate the body’s non-specific immune response.

Source: WHO. Last update 25 August


Please enter your comment!
Please enter your name here